BMS accesses fibrosis programme in $325 million deal for Amira
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb is to acquire Amira Pharmaceuticals for $325 million in cash up front plus milestones of up to $150 million. The deal brings it an early-stage lung fibrosis programme with a lead drug that has yet to enter Phase II studies.